Evidence map›Paper›PMID 25820838›Full record

ArticleInternational orthopaedics2016

Survivorship and clinical outcome of Birmingham hip resurfacing: a minimum ten years' follow-up.

Md Quamar Azam, Stephen McMahon, Gabrielle Hawdon, Sukesh Rao Sankineani

Abstract readClinical Study
PubMed Publisher
In one paragraph

Article in International orthopaedics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Long-term results of Birmingham hip resurfacing arthroplasty in Asian patients.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2018
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Md Quamar AzamKing Fahd Hospital of the University, University of Dammam, Al-Khobar, 31952, Saudi Arabia. qazam47@gmail.com.
Stephen McMahonMalabar Orthopaedic Institute, The Avenue Hospital, 43, The Avenue, Windsor, Melbourne, 3141, Australia. steve.mcmahon@joint-replacements.com.
Gabrielle HawdonMalabar Orthopaedic Institute, The Avenue Hospital, 43, The Avenue, Windsor, Melbourne, 3141, Australia. Gabrielle@joint-replacements.com.
Sukesh Rao SankineaniMalabar Orthopaedic Institute, The Avenue Hospital, 43, The Avenue, Windsor, Melbourne, 3141, Australia. sukeshrao.sankineni@gmail.com.
Imam Abdulrahman Bin Faisal University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionResurfacing as a percentage of total hip arthroplasty rose from 5.6 % in 2001 to 8.9 % in 2005 in Australia. During the same period the resurfacing to conventional prosthesis rose from 19.6 % to 29 % in the younger age group (less than 55 years). Long term (more than ten years) functional results of BHR are sparingly documented. Among the literatures available, the patient selection criteria vary from osteoarthritis, avascular necrosis, and dysplastic hip to slipped capital femoral epiphysis. The objective of the current study is to evaluate long term survivorship and functional outcome of Birmingham hip resurfacing surgery in osteoarthritic hip patients performed by a single surgeon. PATIENTS AND

methodsIn this retrospective clinical study, all patients who underwent hip resurfacing for osteoarthritis of hip between 1999 and 2004 are included. All surgeries were performed by single surgeon (SJM) and in all patients Smith & Nephew system (Midland Medical Technologies, Birmingham, United Kingdom)) was used. Revision surgery is considered the end point of survivorship. Means, standard deviations, and confidence interval were calculated for all continuous measures. Survival analysis was performed with the Kaplan-Meier method and 95 % confidence intervals were calculated.

resultThe result is based on 222 patients (244 hips). This included 153 males and 69 females. Our mean follow up was 12.05 years and overall survival was 93.7 %. In terms of gender, survival in males was 95.43 % while in females it was 89.86 %. Failure was seen in 14 patients (16 hips), which included seven female (10.14 %) and seven male (4.57 %) patients. Failure of femoral components due to aseptic loosening and varus collapse was seen in eight patients after a mean 9.6 years. Metal allergy was seen in three patients (five hips), all of them were female of which two had bilateral resurfacing. Other complications included femoral neck stress fractures in two patients and acetabular component loosening in one patient. We observed that the failure rate is higher if the BHR femoral component size is 46 or less (ten out of 16 hips revised).

conclusionIf patient selection is judiciously done and surgical technique is meticulously followed, hip resurfacing offers acceptable survivorship, satisfactory range of motion and enables patients to resume high demand activities including sports. Future improvements in the bearing surfaces, and possibly in the design, might alleviate concerns posed by high serum metal level and provide options that continue to benefit younger patients in future.

Indexed as

Hip ProsthesisAdultAgedArthroplasty, Replacement, HipFemaleFollow-Up StudiesHip JointHumansMaleMiddle AgedOsteoarthritis, HipPostoperative ComplicationsProsthesis FailureRange of Motion, ArticularReoperationRetrospective StudiesBHRLong termOutcomeSurvivorship

Identifiers

PMID25820838
OpenAlexW2009243771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.